Advertisement
"The American Red Cross is one of the largest and most prestigious healthcare organizations in the United States and these five laboratories testapproximately seven million units of blood annually," said Dr. Gioacchino DeChirico, President and CEO of Immucor. "We are very pleased the American RedCross has chosen the Galileo system for its laboratories. We expect theseinstruments to generate a total of at least $5 million a year in new reagentrevenue after they are all live, depending on the amount and type of testingdone on each instrument."
Advertisement
Founded in 1982, Immucor manufactures and sells a complete line ofreagents and systems used by hospitals, reference laboratories and donorcenters to detect and identify certain properties of the cell and serumcomponents of blood prior to transfusion. Immucor markets a complete familyof automated instrumentation for all of its market segments.
For more information on Immucor, please visit our website athttp://www.immucor.com.
Statements contained in this press release that are not statements ofhistorical fact are "forward-looking statements" as that term is defined underfederal securities laws, including, without limitation, all statementsconcerning Immucor's expectations, beliefs, intentions or strategies for thefuture. Forward-looking statements may be identified by words such as"plans," "expects," "believes," "anticipates," "estimates," "projects,""will," "should" and other words of similar meaning. Investors are cautionednot to place undue reliance on any forward-looking statements. In particular,our financial results may be adversely impacted by the inability of theAmerican Red Cross to effectively integrate our Galileo instruments into theirblood testing operations. Further risks are detailed in the Company's filingswith the Securities and Exchange Commission. Immucor assumes no obligation toupdate any forward-looking statements.
SOURCE Immucor, Inc.
